Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

YOU WONT BELIEVE: Benzinga s top ratings upgrades downgrades for march 7 2022 - You Need To See This

Upgrades

According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics showed an EPS of $1.09, compared to $0.69 from the year-ago quarter. The stock has a 52-week-high of $202.73 and a 52-week-low of $43.86. At the end of the last trading period, Intellia Therapeutics closed at $65.04.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.